Inactive Instrument

Cambrex Corporation

CBM

Cambrex Corporation Appoints Wayne Hewett as Chairman of the Board of Directors

December 04, 2019 at 09:27 am

Cambrex Corporation announced the appointment of Wayne Hewett as Chairman of the Board of Directors. Mr. Hewett is a seasoned industry executive with deep operational and leadership experience across multiple industries. He currently serves as the Chairman of DiversiTech, a Permira portfolio company, and is a board member of Wells Fargo and The Home Depot.

Latest news about Cambrex Corporation

Noramco, Inc. acquired Drug Product Business Unit of Cambrex Corporation.	11-01	CI
Noramco, Inc. acquired Halo Pharma, Inc. from Cambrex Corporation.	11-01	CI
Cambrex Announces Grand Opening of New First Stability Storage Commercial Agreement	23-05-31	CI
Cambrex Opens New Stability Storage Facility in Belgium	23-04-04	CI
Cambrex Corporation completed the acquisition of Snapdragon Chemistry, Inc.	23-01-17	CI
Cambrex Corporation entered into a definitive agreement to acquire Snapdragon Chemistry, Inc.	22-11-20	CI
Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa	22-10-27	CI
Cambrex Corporation Announces Stability Storage Expansions in Ireland and Belgium	22-10-04	CI
Cambrex Completes First Phase of $30 Million Capacity Expansion Project in High Point, North Carolina	22-09-01	CI
Cambrex Corporation acquired Q1 Scientific Limited.	22-05-31	CI
Cambrex Completes Large-Scale US API Expansion	22-04-12	CI
Cambrex Corporation Expands Biopharmaceutical Services Business	22-03-01	CI
Cambrex to Invest $30 Million to Expand Manufacturing Center of Excellence At High Point, NC Facility	21-10-07	CI
Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar	21-06-23	CI
Cambrex Introduces New Kilogram-Scale Gmp Manufacturing Capabilities At Tallinn, Estonia Facility	21-05-26	CI
Cambrex Expands Analytical Services Capabilities at Longmont, Colorado, Facility	21-05-05	CI
Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabilities in the U.S	20-11-17	CI
Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh	20-10-12	CI
Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility	20-07-01	CI
Cambrex Appoints Thomas Loewald as Member of the Board of Directors Effective September 7, 2020	20-06-18	CI
Cambrex Appoints Thomas Loewald as Chief Executive Officer Effective September 7, 2020	20-06-18	CI
Cambrex Announces Management Changes	20-06-02	CI
Cambrex Announces Board Changes	20-06-02	CI
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility	20-04-07	CI
Cambrex Appoints Troy Player as President, Early Stage Development and Testing	20-03-31	CI

Chart Cambrex Corporation

Duration

Period

More charts

Company Profile

Cambrex Corporation (Cambrex) is a United States-based small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. The Company offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and potent application program interface. In addition, it also supports conventional dosage forms including oral solids, semi-solids and liquids and has the capabilities to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals